Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 600x60px
Document › Details

Medigene AG. (7/15/14). "Press Release: Medigene Secures Funding for Its Cancer Immunotherapy Programmes through Capital Increase [Not for release, publication or distribution in the United States, Canada, Japan or Australia]". Martinsried.

Organisation Organisation Medigene AG (FSE: MDG1, Prime Standard)
  Group Medigene (Group)
Products Product T cell therapy
  Product 2 investment banking
Index terms Index term Medigene–SEVERAL: investment, 201406–201407 capital increase €15.9m 3m new shares + 818.7k convertible bonds
  Index term 2 Trianta Immunotherapies–Medigene: investment, 201401 acquisition 100% for 1m shares worth €4m plus €5.875m milestones in shares or cash
Persons Person Llewellyn-Davies, Peter (Apeiron 201807– CEO before CFO+CBO before Accellerate Partners + Medigene + Wilex)
  Person 2 Schendel, Dolores J. (Medigene 201602– CEO before CMO before Trianta Immunotherapies + HelmholtzZentrum München)

Record changed: 2017-04-02


Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px

More documents for Medigene (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSUS] – The Business Web Portal 600x60px

» top